Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ETNB NASDAQ:FDMT NYSE:NUVB NASDAQ:WVE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeETNB89BIO$8.07-6.7%$9.49$4.16▼$11.84$1.28B1.271.34 million shs717,738 shsFDMT4D Molecular Therapeutics$6.81-3.7%$5.70$2.23▼$17.41$318.04M2.86617,578 shs517,375 shsNUVBNuvation Bio$3.14-6.3%$2.65$1.54▼$4.09$1.07B1.366.16 million shs7.93 million shsWVEWAVE Life Sciences$6.97-2.7%$8.49$5.28▼$16.74$1.14B-1.152.29 million shs1.85 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceETNB89BIO-6.71%-9.02%-11.71%-22.48%-0.49%FDMT4D Molecular Therapeutics-3.68%-6.33%+2.10%+55.13%-56.68%NUVBNuvation Bio-6.27%-19.09%+20.77%+82.03%+2.28%WVEWAVE Life Sciences-2.65%-15.92%-20.43%+0.29%+18.14%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeETNB89BIO$8.07-6.7%$9.49$4.16▼$11.84$1.28B1.271.34 million shs717,738 shsFDMT4D Molecular Therapeutics$6.81-3.7%$5.70$2.23▼$17.41$318.04M2.86617,578 shs517,375 shsNUVBNuvation Bio$3.14-6.3%$2.65$1.54▼$4.09$1.07B1.366.16 million shs7.93 million shsWVEWAVE Life Sciences$6.97-2.7%$8.49$5.28▼$16.74$1.14B-1.152.29 million shs1.85 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceETNB89BIO-6.71%-9.02%-11.71%-22.48%-0.49%FDMT4D Molecular Therapeutics-3.68%-6.33%+2.10%+55.13%-56.68%NUVBNuvation Bio-6.27%-19.09%+20.77%+82.03%+2.28%WVEWAVE Life Sciences-2.65%-15.92%-20.43%+0.29%+18.14%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceETNB89BIO 3.00Buy$28.00246.96% UpsideFDMT4D Molecular Therapeutics 2.64Moderate Buy$30.40346.40% UpsideNUVBNuvation Bio 3.17Buy$7.50138.85% UpsideWVEWAVE Life Sciences 2.93Moderate Buy$20.33191.73% UpsideCurrent Analyst Ratings BreakdownLatest FDMT, NUVB, WVE, and ETNB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/8/2025NUVBNuvation BioWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$6.009/4/2025WVEWAVE Life SciencesB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy9/4/2025WVEWAVE Life SciencesWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$21.00 ➝ $18.009/4/2025ETNB89BIOHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$32.009/3/2025WVEWAVE Life SciencesLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$26.009/3/2025WVEWAVE Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$22.008/30/2025ETNB89BIOWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated Rating8/30/2025FDMT4D Molecular TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated Rating8/25/2025ETNB89BIOBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$30.00 ➝ $29.008/14/2025ETNB89BIOWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated Rating8/14/2025FDMT4D Molecular TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated Rating(Data available from 9/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookETNB89BION/AN/AN/AN/A$3.34 per shareN/AFDMT4D Molecular Therapeutics$33K9,637.59N/AN/A$11.05 per share0.62NUVBNuvation Bio$14.36M74.87N/AN/A$1.37 per share2.29WVEWAVE Life Sciences$108.30M10.24N/AN/A$1.37 per share5.09Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateETNB89BIO-$367.08M-$3.61N/AN/AN/AN/A-94.48%-80.92%11/6/2025 (Estimated)FDMT4D Molecular Therapeutics-$160.87M-$3.53N/AN/AN/A-594,375.81%-40.15%-36.43%11/12/2025 (Estimated)NUVBNuvation Bio-$567.94M-$0.63N/AN/AN/A-1,413.43%-46.14%-36.04%11/5/2025 (Estimated)WVEWAVE Life Sciences-$97.01M-$0.90N/AN/AN/AN/A-78.45%-41.51%11/11/2025 (Estimated)Latest FDMT, NUVB, WVE, and ETNB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025FDMT4D Molecular Therapeutics-$0.88-$0.98-$0.10-$0.98$0.52 million$0.01 million8/7/2025Q2 2025ETNB89BIO-$0.49-$0.71-$0.22-$0.71N/AN/A8/7/2025Q2 2025NUVBNuvation Bio-$0.17-$0.17N/A-$0.17$0.42 million$4.83 million7/30/2025Q2 2025WVEWAVE Life Sciences-$0.29-$0.31-$0.02-$0.31$11.52 million$8.70 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthETNB89BION/AN/AN/AN/AN/AFDMT4D Molecular TherapeuticsN/AN/AN/AN/AN/ANUVBNuvation BioN/AN/AN/AN/AN/AWVEWAVE Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioETNB89BIO0.0715.1915.19FDMT4D Molecular TherapeuticsN/A8.758.75NUVBNuvation Bio0.139.399.38WVEWAVE Life SciencesN/A2.562.56Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipETNB89BION/AFDMT4D Molecular Therapeutics99.27%NUVBNuvation Bio61.67%WVEWAVE Life Sciences89.73%Insider OwnershipCompanyInsider OwnershipETNB89BIO2.60%FDMT4D Molecular Therapeutics9.60%NUVBNuvation Bio29.93%WVEWAVE Life Sciences23.98%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableETNB89BIO40148.31 million144.45 millionOptionableFDMT4D Molecular Therapeutics12046.70 million42.22 millionOptionableNUVBNuvation Bio60342.27 million239.83 millionOptionableWVEWAVE Life Sciences240159.14 million120.98 millionOptionableFDMT, NUVB, WVE, and ETNB HeadlinesRecent News About These CompaniesWAVE Life Sciences (NASDAQ:WVE) Stock Price Down 3.5% - What's Next?1 hour ago | marketbeat.comWave Life Sciences (WVE) Sees Promising Results From RestorAATion-2 StudySeptember 10 at 5:43 PM | finance.yahoo.comRaymond James Reaffirms Their Buy Rating on Wave Life Sciences (WVE)September 9, 2025 | theglobeandmail.comPolar Asset Management Partners Inc. Has $221,000 Stock Holdings in WAVE Life Sciences Ltd. $WVESeptember 9, 2025 | marketbeat.comLeerink Partnrs Has Positive Outlook of WVE FY2027 EarningsSeptember 9, 2025 | marketbeat.comWave Life Sciences Announces Positive Results for WVE-006 StudySeptember 8, 2025 | theglobeandmail.comTrexquant Investment LP Sells 215,940 Shares of WAVE Life Sciences Ltd. $WVESeptember 7, 2025 | marketbeat.comWAVE Life Sciences Ltd. $WVE Stock Position Boosted by Invesco Ltd.September 7, 2025 | marketbeat.comB. Riley ‘aggressive’ buyer of Wave Life on ‘material disconnect’September 6, 2025 | finance.yahoo.comHC Wainwright Reiterates "Buy" Rating for WAVE Life Sciences (NASDAQ:WVE)September 5, 2025 | marketbeat.comWAVE Life Sciences (NASDAQ:WVE) Shares Gap Down - Should You Sell?September 5, 2025 | marketbeat.comWAVE Life Sciences Ltd. $WVE Shares Purchased by Adage Capital Partners GP L.L.C.September 5, 2025 | marketbeat.comWAVE Life Sciences (NASDAQ:WVE) Earns Buy Rating from HC WainwrightSeptember 5, 2025 | americanbankingnews.comWave Crashes Despite Successful RNA Editing in AATD StudySeptember 4, 2025 | biospace.comB683 Capital Management LLC Purchases 140,000 Shares of WAVE Life Sciences Ltd. $WVESeptember 4, 2025 | marketbeat.comJump Financial LLC Trims Stake in WAVE Life Sciences Ltd. $WVESeptember 4, 2025 | marketbeat.comWave RNA editing restores enzyme in genetic condition but underwhelms investorsSeptember 4, 2025 | fiercebiotech.comFWave shares sink on new study results for RNA editing drugSeptember 4, 2025 | finance.yahoo.comForecasting The Future: 7 Analyst Projections For WAVE Life SciencesSeptember 4, 2025 | benzinga.comWave Life Sciences Tumbled 19% Today, But Not Everyone’s Disappointed – Find Out WhySeptember 4, 2025 | msn.comWave Life Sciences Ltd. (WVE) Positive RestorAATion-2 Clinical Data Update Conference TranscriptSeptember 3, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFDMT, NUVB, WVE, and ETNB Company Descriptions89BIO NASDAQ:ETNB$8.07 -0.58 (-6.71%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$8.53 +0.46 (+5.65%) As of 09/12/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.4D Molecular Therapeutics NASDAQ:FDMT$6.81 -0.26 (-3.68%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$6.81 0.00 (0.00%) As of 09/12/2025 05:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.Nuvation Bio NYSE:NUVB$3.14 -0.21 (-6.27%) Closing price 09/12/2025 03:59 PM EasternExtended Trading$3.14 0.00 (0.00%) As of 09/12/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.WAVE Life Sciences NASDAQ:WVE$6.97 -0.19 (-2.65%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$6.94 -0.02 (-0.36%) As of 09/12/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
